Abstract:BACKGROUND Diabetic nephropathy (DN) is the principal cause of end-stage renal disease. Previous studies have shown that clopidogrel can prevent the early progression of renal injury. AIM To elucidate whether clopidogrel is beneficial against DN by using a db / db mouse model. METHODS db/db mice with a higher urinary albumin/creatinine ratio (ACR) relative to age- and sex-matched wild-type control mice were randomly allocated to clopidogrel and vehicle treatment groups. Clopidogrel was administered at doses of 5, 10, and 20 mg/kg by gavage for 12 wk. Body mass, blood glucose level, and urinary creatinine and albumin concentrations in each group were measured before and after the intervention. Renal fibrosis was evaluated using periodic acid-Schiff and Masson's trichrome staining. The renal protein expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and F4/80 was assessed using immunohistochemistry. Urinary TNF-α, monocyte chemoattractant protein-1 (MCP-1), and IL-6 levels were analyzed using enzyme-linked immunosorbent assay; TNF-α and IL-1β mRNA expression was measured using real-time quantitative polymerase chain reaction. The protein expression of fibronectin (FN) and collagen I was assessed using immunohistochemistry. RESULTS Clopidogrel treatment did not affect the body mass or blood glucose level of the db/db mice; however, it increased bleeding time and reduced urinary ACR in a dose-dependent manner. Immunohistochemical staining revealed an amelioration of renal fibrosis, significantly lower deposition of FN and collagen I, and significantly lower expression of the proinflammatory cytokines TNF-α and IL-1β and lower levels of urinary TNF-α and MCP-1 in the clopidogrel-treated db/db mice ( P < 0.05). Furthermore, clopidogrel significantly reduced macrophage infiltration into the glomeruli of the db/db mice. CONCLUSION Clopidogrel significantly reduced renal collagen deposition and fibrosis and prevented renal dysfunction in db / db mice, most likely through inhibition of renal macrophage infiltration and the associated inflammation. Key Words: Diabetes, Clopidogrel, Inflammation, Fibronectin, Diabetic nephropathy Core Tip: Diabetic nephropathy is the most common microvascular inflammatory disease among the diabetic complications. Previous studies have shown that clopidogrel administration is an effective means of suppressing inflammation in diseases such as acute myocardial infarction, diabetes, and acute ischemic cerebral infarction. In this study, we aimed to determine whether treatment with clopidogrel has a preventive or therapeutic effect in the kidneys of obese, type 2 diabetic db/db mice. In this experiment, we demonstrated that clopidogrel significantly reduced renal collagen deposition and fibrosis and prevented renal dysfunction in db/db mice, most likely through inhibition of renal macrophage infiltration and the associated inflammation. Citation: Li HQ, Liu N, Zheng ZY, Teng HL, Pei J. Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice. World J Diabetes 2022; 13(8): 600-612 URL: https://www.wjgnet.com/1948-9358/full/v13/i8/600.htm DOI: https://dx.doi.org/10.4239/wjd.v13.i8.600

A BROADBAND X-RAY STUDY OF THE GEMINGA PULSAR WITH NuSTAR AND XMM-NEWTON

Advanced Interfere Treatment of Diabetic Cardiomyopathy Rats by Afgf-Loaded Heparin-Modified Microbubbles and UTMD Technique

Combined Treatment with Ultrasound-Targeted Microbubble Destruction Technique and NM-aFGF-loaded PEG-nanoliposomes Protects Against Diabetic Cardiomyopathy-Induced Oxidative Stress by Activating the AKT/GSK-3β1/Nrf-2 Pathway

Clopidogrel delays and can reverse diabetic nephropathy pathogenesis in type 2 diabetic db/db mice

Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy

The Protective effect of CGPR on cardiac function in the early-staged diabetic mice postiscbemic injury

Quercetin ameliorated cardiac injury via reducing inflammatory actions and the glycerophospholipid metabolism dysregulation in a diabetic cardiomyopathy mouse model

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

Exogenous Spermidine Alleviates Diabetic Myocardial Fibrosis Via Suppressing Inflammation and Pyroptosis in db/db Mice

Flower Color Microevolution in Wild Radish: Evolutionary Response to Pollinator‐Mediated Selection

Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

Clopidogrel Resistance in a Murine Model of Diet-Induced Obesity is Mediated by the Interleukin-1 Receptor and Overcome with DT-678.

D‐pinitol alleviates diabetic cardiomyopathy by inhibiting the optineurin‐mediated endoplasmic reticulum stress and glycophagy signaling pathway

Abstract 13045: Chronic Beta3-Adrenergic Receptor Antagonist Therapy Rescues Diabetic Cardiomyopathy in a Mouse Model With Type 2 Diabetes: Insights into Cellular Mechanism

Pharmacologic Activation of Angiotensin-Converting Enzyme II Alleviates Diabetic Cardiomyopathy in db/db Mice by Reducing Reactive Oxidative Stress

Compound c17 alleviates inflammatory cardiomyopathy in streptozotocin-induced diabetic mice by targeting MyD88

Inhibition of JNK and P38 MAPK‐mediated Inflammation and Apoptosis by Ivabradine Improves Cardiac Function in Streptozotocin‐induced Diabetic Cardiomyopathy

Gamblers' self-perceptions of the determinants of impaired control.

Abstract 13035: Beta3-Adrenergic-Receptor-Deficient Mice Protected From Diabetic Cardiomyopathy in Type 2 Diabetic Murine Model: Beneficial Effects on Cardiomyocyte Contractile Function, [Ca 2+ ] i Regulation and Beta-Adrenergic Modulation

Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy

Abstract 9024: Molecular Mechanism of Chronic Beta3-Adrenergic Receptor Antagonist Caused Regression of Diabetic Cardiomyopathy in a Murine Model With Type 2 Diabetes